Boston Scientific Discontinues Aortic Valve Systems

Boston Scientific ( (BSX) ) has provided an update.

On May 28, 2025, Boston Scientific announced the discontinuation of its ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems, ceasing global sales and halting pursuit of FDA approval due to increased regulatory demands. Despite the financial implications, the company expects to meet its sales and earnings guidance for 2025, though it is withholding reaffirmation of its GAAP EPS guidance until further updates in its second quarter earnings call.

The most recent analyst rating on (BSX) stock is a Buy with a $113.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.

Spark’s Take on BSX Stock

According to Spark, TipRanks’ AI Analyst, BSX is a Outperform.

Boston Scientific exhibits a strong financial performance with robust revenue growth and operational efficiency. The earnings call provided positive guidance, reinforcing growth prospects despite challenges like tariffs and foreign exchange impacts. However, the high valuation metrics suggest potential overvaluation, and technical indicators indicate a possible overbought condition, which could lead to future stock price corrections. Overall, the company maintains a favorable position in the medical devices sector.

To see Spark’s full report on BSX stock, click here.

More about Boston Scientific

Boston Scientific Corporation operates in the medical device industry, focusing on the development and manufacturing of products for various medical conditions, including cardiovascular diseases.

Average Trading Volume: 8,401,090

Technical Sentiment Signal: Buy

Current Market Cap: $157.1B

Find detailed analytics on BSX stock on TipRanks’ Stock Analysis page.